Real-World Effectiveness of Cannabidiol on Antiseizure Medication Cycling, Polypharmacy, and Healthcare Resource Utilization: A US Claims Analysis.

Updated or extended 2026 analysis of CBD effectiveness on ASM cycling, polypharmacy, and HCRU in epilepsy patients, building on the 2025 study (Row 105). Jazz Pharmaceuticals funded.

Target RWE researchers provided updated or extended real-world effectiveness analyses of CBD on antiseizure medication cycling, polypharmacy burden, and healthcare resource utilization, funded by Jazz Pharmaceuticals.

Updated post-market CBD effectiveness evidence extends the duration and scope of the real-world evidence base for Jazz Pharmaceuticals, supporting ongoing label messaging, formulary negotiations, and prescriber education programs.

Updated CBD post-market effectiveness evidence for ASM cycling and polypharmacy for Jazz Pharmaceuticals, Extended real-world cannabidiol effectiveness data for treatment-resistant epilepsy payer and label strategy